title: [Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells].
abstract: The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) on chronic leukemia. The apoptosis of K562/A02 cells treated by DNA, BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry; the expressions levels of survivin mRNA and protein K562/A02 cells treated by DNR, BrTet and BrTet combined with DNR and in untreated K562 cells for 48 hours were measured by RT-PCR and Western blot respectively. The results showed that the combination of BrTet with DNR increased apoptotic rate of K562/A02, down-regulated the expression levels of survivin mRNA and protein in K562/A02 cells as compared with blank control and cells treated by BrTet or DNR alone, the survivin expression in K562/A02 cells was higher than that in K562 cells. It is concluded that the combination of BrTet with DNR can effectively reverse the multidrug resistance of K562/A02 cells, promote the apoptosis of K562/A02 cells, the mechanism of which may be related with down-regulation of survivin expression. Survivin may be a target for the treatment of MDR in hematopoietic malignancies.
authors.affiliation: Department of Hematology, Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China.
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Cai
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Cheng
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Wen
authors.initials: W
authors.lastname: Bao
authors.forename: Yue-Jiao
authors.initials: YJ
authors.lastname: Zhong
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Wen-Lin
authors.initials: WL
authors.lastname: Xu
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Shen
authors.forename: Hu-Lai
authors.initials: HL
authors.lastname: Wei
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D044182:Benzylisoquinolines / Q000494:pharmacology*; D003630:Daunorubicin / Q000494:pharmacology*; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D020014:K562 Cells; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D044182:Benzylisoquinolines; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; C514835:bromotetrandrine; D003630:Daunorubicin